Floatz logo

Vebreltinib

Hereditary Gingival Fibromatosis

Explore 1 assets in Hereditary Gingival Fibromatosis →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Apollomics Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT03175224CT.gov
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hereditary Gingival Fibromatosis

AssetSponsorPhaseRating
Vebreltinib (this asset)Apollomics Inc.P2CCC · 53

Other indications for Vebreltinib

IndicationSponsorPhaseRating
Non-Small Cell Lung Carcinoma—P3BBB · 73
Renal Cell Carcinoma—P2B · 58
Glioblastoma—P2/3CCC · 54

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Vebreltinib in Hereditary Gingival Fibromatosis. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/vebreltinib-hereditary-gingival-fibromatosis

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →